Immunic receives notice of allowance for united states patent protecting vidofludimus calcium's dosing regimens in multiple sclerosis

– fundamental new patent covers treatment of multiple sclerosis into 2038 and beyond – – third u.s. patent directed to use of vidofludimus calcium in multiple sclerosis – – multilayered intellectual property strategy provides protection into 2041 in the u.s. and into 2038 internationally, unless extended further – – adds on recently allowed u.s. patent protecting specific dose strength for relapsing multiple sclerosis treatment – new york , nov. 21, 2023 /prnewswire/ -- immunic, inc.  (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that it has received a notice of allowance from the united states patent and trademark office (uspto) for patent application 17/992,162, entitled, "compounds and dosage regimen for use in the prevention or treatment of chronic inflammatory and/or autoimmune diseases." specifically, the resulting patent covers dosing regimens associated with lead asset, vidofludimus calcium (imu-838), and other salt forms as well as free acid forms for the treatment of multiple sclerosis (ms), including all regimens tested in the company's ms clinical program.
IMUX Ratings Summary
IMUX Quant Ranking